Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Do persons with diabetes benefit from combination statin and fibrate therapy?

Rosenblit PD.

Curr Cardiol Rep. 2012 Feb;14(1):112-24. doi: 10.1007/s11886-011-0237-7. Review.

PMID:
22213157
2.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

3.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

4.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
5.

Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Agouridis AP, Rizos CV, Elisaf MS, Filippatos TD.

Rev Diabet Stud. 2013 Summer-Fall;10(2-3):171-90. doi: 10.1900/RDS.2013.10.171. Epub 2013 Aug 10. Review.

6.
7.

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.

Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN.

Expert Opin Pharmacother. 2011 Jun;12(9):1429-38. doi: 10.1517/14656566.2011.563506. Epub 2011 Mar 23. Review.

PMID:
21426238
8.

Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.

Wanner C, Krane V.

Kidney Blood Press Res. 2011;34(4):209-17. doi: 10.1159/000326849. Epub 2011 Jun 21. Review.

9.

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.

Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B.

Atherosclerosis. 2011 Aug;217(2):492-8. doi: 10.1016/j.atherosclerosis.2011.04.020. Epub 2011 Apr 27. Review.

PMID:
21592479
10.

Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?

Milionis H.

Expert Opin Drug Saf. 2014 Mar;13(3):267-9. doi: 10.1517/14740338.2014.887679. Epub 2014 Feb 10.

PMID:
24512564
11.

How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.

Steiner G.

Cardiovasc Drugs Ther. 2009 Oct;23(5):403-8. doi: 10.1007/s10557-009-6190-7. Review.

PMID:
19757004
12.

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

Moutzouri E, Kei A, Elisaf MS, Milionis HJ.

Vasc Health Risk Manag. 2010 Aug 9;6:525-39. Review.

13.

Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?

Brinton EA.

Curr Atheroscler Rep. 2008 Feb;10(1):25-32. Review.

PMID:
18366982
14.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
15.

Hyperlipidaemia and cardiovascular disease: do fibrates have a role?

Saha SA, Arora RR.

Curr Opin Lipidol. 2011 Aug;22(4):270-6. doi: 10.1097/MOL.0b013e32834701c3. Review.

PMID:
21519250
16.

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.

Am J Cardiovasc Drugs. 2010;10(2):73-84. doi: 10.2165/10061630-000000000-00000.

PMID:
20136164
17.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

18.

Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found.

Toth PP.

Curr Atheroscler Rep. 2010 Sep;12(5):331-5. doi: 10.1007/s11883-010-0126-3. Review.

PMID:
20623343
19.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
20.

Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.

Matikainen N, Taskinen MR.

Curr Cardiol Rep. 2012 Dec;14(6):721-31. doi: 10.1007/s11886-012-0309-3. Review.

PMID:
22941588

Supplemental Content

Support Center